RZLT

Rezolute Inc

RZLT, USA

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

https://www.rezolutebio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
RZLT
stock
RZLT

Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure marketscreener.com

Read more →
RZLT
stock
RZLT

Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ StocksToTrade

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$15.7778

Analyst Picks

Strong Buy

7

Buy

3

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

1.26

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-12.33 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-11.44 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.08

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 127.29% of the total shares of Rezolute Inc

1.

Federated Hermes Inc

(16.1326%)

since

2025/06/30

2.

FMR Inc

(14.727%)

since

2025/06/30

3.

Federated Hermes Kaufmann R

(8.0337%)

since

2025/06/30

4.

Federated Hermes Kaufmann Growth

(6.8727%)

since

2025/06/30

5.

Federated Hermes Kaufmann Small Cap A

(5.9609%)

since

2025/06/30

6.

Federated Hermes Kaufmann Small Cap Grow

(4.9955%)

since

2025/06/30

7.

BlackRock Inc

(4.6916%)

since

2025/06/30

8.

Vanguard Group Inc

(4.6239%)

since

2025/06/30

9.

Blackstone Inc

(4.0925%)

since

2025/06/30

10.

UBS Group AG

(3.4912%)

since

2025/06/30

11.

Great Point Partners LLC

(3.4869%)

since

2025/06/30

12.

Marshall Wace Asset Management Ltd

(3.3179%)

since

2025/06/30

13.

Fidelity Select Health Care

(3.2185%)

since

2025/07/31

14.

Fidelity Advisor Biotechnology I

(3.1555%)

since

2025/07/31

15.

Mangrove Partners

(2.6409%)

since

2025/06/30

16.

Nantahala Capital Management, LLC

(2.6339%)

since

2025/06/30

17.

Vanguard Total Stock Mkt Idx Inv

(2.5608%)

since

2025/07/31

18.

Affinity Asset Advisors, LLC

(2.5289%)

since

2025/06/30

19.

Fidelity Stock Selector Small Cap

(2.4925%)

since

2025/06/30

20.

Vivo Capital, LLC

(2.4282%)

since

2025/06/30

21.

Fidelity Series Small Cap Opps

(2.1994%)

since

2025/06/30

22.

Woodline Partners LP

(2.1888%)

since

2025/06/30

23.

Integral Health Asset Management, LLC

(2.0691%)

since

2025/06/30

24.

Rosalind Advisors, Inc.

(2.0015%)

since

2025/06/30

25.

Geode Capital Management, LLC

(1.9668%)

since

2025/06/30

26.

iShares Russell 2000 ETF

(1.8514%)

since

2025/08/31

27.

Caxton Corp

(1.8437%)

since

2025/06/30

28.

Fidelity Advisor Health Care I

(1.8392%)

since

2025/07/31

29.

Caligan Partners LP

(1.7737%)

since

2025/06/30

30.

ADAR1 Capital Management LLC

(1.1372%)

since

2025/06/30

31.

Opaleye Management Inc

(1.0385%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9045%)

since

2025/07/31

33.

Fidelity Small Cap Index

(0.7716%)

since

2025/06/30

34.

Fidelity Select Biotechnology

(0.7254%)

since

2025/07/31

35.

MEDICAL BioHealth EUR Acc

(0.7024%)

since

2025/06/30

36.

iShares Russell 2000 Growth ETF

(0.5966%)

since

2025/08/31

37.

Fidelity VIP Health Care Initial

(0.5173%)

since

2025/07/31

38.

Fidelity Extended Market Index

(0.4386%)

since

2025/07/31

39.

Vanguard Russell 2000 ETF

(0.3671%)

since

2025/07/31

40.

State St Russell Sm Cap® Indx SL Cl I

(0.2715%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.18

EPS Estimate

-0.2234

EPS Difference

0.0434

Surprise Percent

19.427%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.